ALLMedicine™ Factor XI Deficiency Center

Mar 21st, 2023 - Congenital factor XI deficiency is a coagulopathy probably underestimated that confers antithrombotic protection. Characterization of genetic defects in F11 is mainly focused on the identification of single nucleotide variants and small insertion/...

Jan 26th, 2023 - Factor (F) XI deficiency is associated with increased bleeding risk in some individuals. Neither FXI levels nor clinical clotting assays predict the bleeding risk. Compared with controls, FXI-deficient bleeders have reduced clot formation, decreas...

Jan 5th, 2023 - Factor XI (FXI) deficiency is a rare bleeding disorder of unpredictable severity that correlates poorly with FXI coagulation activity and that poses great challenges for perioperative hemostatic management and the dialysis methods potentially avai...

Dec 16th, 2022 - Factor XI (FXI) deficiency is an autosomally inherited milder bleeding disorder which may predispose to a potential risk of life-threatening bleeding during childbirth or surgery. Unfortunately, data regarding obstetric and perioperative managemen...

Dec 15th, 2022 - Practice Essentials Abnormalities in the coagulation cascade that are independent of platelet mechanisms can affect hemostasis. These abnormalities may be inherited or acquired. Disorders of nonplatelet hemostasis can be divided into 2 groups base...

Sep 12th, 2017 - The most frequent inherited coagulation disorders are haemophilia A and B, due to the deficiency of factor VIII and IX. Haemophilia A and B are clinically indistinguishable from each other and occur in mild, moderate and severe forms (with plasma f...

Aug 23rd, 2013 - Many patients are asymptomatic until hemostatically challenged by surgery or trauma; so, the diagnosis is often made in late childhood or early adulthood but always after full liver maturation (i.e. 6 months) as reported by Andrew et al. Spontaneo...

Feb 23rd, 2012 - Eligible patients will be those with severe factor XI deficiency who agree to participate in the study . The treatment does not apply to patients requiring coronary artery bypass or other vascular surgery.

Aug 28th, 2022 - The new factor XI inhibitor antithrombotic, milvexian (BMS/Janssen), has shown promising results in a dose-finding phase 2 trial in patients with acute ischemic stroke or transient ischemic attack (TIA), when given in addition to dual antiplatelet...

Mar 13th, 2019 - When managed by an experienced team, patients with inherited bleeding disorders undergoing gastrointestinal endoscopy are not at increased bleeding risk, according to researchers reporting the largest series of such patients to date. The postendos.

Apr 7th, 2017 - Image by Spencer Phillips DNA helix The US Food and Drug Administration (FDA) has authorized marketing of 23andMe Personal Genome Service (PGS) Genetic Health Risk (GHR) tests for 10 medical conditions. These are the first direct-to-consumer tests.

Apr 6th, 2017 - In the latest step toward personalized medicine, the US Food and Drug Administration (FDA) today approved the first direct-to-consumer (DTC) genetic tests that provide information on a person's risk of developing a disease. The tests in question, ...

Feb 20th, 2015 - SAN FRANCISCO – Reducing factor XI levels with the experimental antisense oligonucleotide FXI-ASO lowered venous thromboembolism rates after total knee arthroplasty without increasing bleeding in a phase II study. Venous thromboembolism (VTE) rate.